argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
